Advertisement
Screener

CLIMB BIO, INC. (CLYM) Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

CLIMB BIO, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities

CLIMB BIO, INC. (CLYM) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$589.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06

  • CLIMB BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $943.00K.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$1.53M, a 175.28% decline year-over-year.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $220.00K, a 78.52% decline year-over-year.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$792.00K, a 933.68% decline year-over-year.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $372.00K, a 74.26% decline from fiscal 2024.
  • CLIMB BIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.45M.
Period endIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month
2026-06-30$943.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$589.00K
10-Q · filed 2026-08-06
-$369.00K
derived: sum of 3 quarters · filed 2026-08-06
-$1.16M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$1.53M
10-Q · filed 2026-05-07
-$1.31M
derived: sum of 2 quarters · filed 2026-05-07
-$2.10M
derived: sum of 3 quarters · filed 2026-05-07
-$3.19M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$220.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$572.00K
derived: sum of 2 quarters · filed 2026-03-05
-$1.66M
derived: sum of 3 quarters · filed 2026-08-06
$372.00K
10-K · filed 2026-03-05
2025-09-30-$792.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$1.88M
derived: sum of 2 quarters · filed 2026-08-06
$152.00K
10-Q · filed 2025-11-06
$1.18M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$1.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$944.00K
10-Q · filed 2026-08-06
$1.97M
derived: sum of 3 quarters · filed 2026-08-06
$2.06M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$2.04M
10-Q · filed 2026-05-07
$3.06M
derived: sum of 2 quarters · filed 2026-05-07
$3.15M
derived: sum of 3 quarters · filed 2026-05-07
2024-12-31$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$1.12M
derived: sum of 2 quarters · filed 2026-03-05
$1.45M
10-K · filed 2026-03-05
2024-09-30$95.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$421.00K
10-Q · filed 2025-11-06
2024-06-30$326.00K
10-Q · filed 2025-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
Verastem, Inc. (VSTM)United States$0.706B-1.71
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
Neurogene Inc. (NGNE)$0.625B-4.46
Faeth Therapeutics, Inc. (FTH)United States$0.750B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47